Valuation: Tsubota Laboratory Incorporated

Market Cap 6.45B 40.93M 36.6M 33.86M 30.66M 57.38M 3.89B 58.32M 407M 161M 2.04B 154M 150M P/E 2025
49.7x
P/E 2026 -9.95x
Enterprise Value 5.55B 35.21M 31.48M 29.13M 26.37M 49.36M 3.35B 50.17M 351M 139M 1.75B 132M 129M EV / Sales 2025
6.38x
EV / Sales 2026 33.4x
Free-Float
28.38%
Yield 2025 *
-
Yield 2026 -
08-11 Tsubota Laboratory Incorporated Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
06-16 Tsubota Laboratory Incorporated announced that it has received ¥4.129362 million in funding from Cantor Fitzgerald Europe CI
05-31 Tsubota Laboratory Incorporated announced that it expects to receive ¥4.129362 million in funding from Cantor Fitzgerald Europe CI
05-31 Tsubota Laboratory Incorporated signed a letter of intent to acquire MediProduce, Inc. from Eri Kubota for ¥150 million. CI
05-15 Tsubota Laboratory Incorporated Reports Earnings Results for the Full Year Ended March 31, 2026 CI
05-15 Tsubota Laboratory Incorporated Provides Non Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027 CI
02-13 Tsubota Laboratory Incorporated Provides Non Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2026 CI
02-13 Tsubota Laboratory Incorporated Reports Earnings Results for the Nine Months Ended December 31, 2025 CI
11/05/25 Tsubota Laboratory Incorporated Provides Earnings Guidance for the Fiscal Year Ending March 31, 2026 CI
17/02/25 Tsubota Laboratory Incorporated Revises Earnings Guidance for the Fiscal Year Ending March 31, 2025 CI
20/11/24 Tsubota Laboratory Incorporated Provides Earnings Guidance for the Fiscal Year Ending March 31, 2025 CI
18/12/22 Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 19-DEC-2022. CI
19/09/22 Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 20-SEP-2022. CI
1 day-0.80%
1 week-4.98%
Current month-1.59%
1 month-3.12%
3 months+2.06%
6 months-15.93%
Current year-27.06%
1 week 246
Extreme 246
263
1 month 242
Extreme 242
285
Current year 210
Extreme 210
478
1 year 210
Extreme 210
478
3 years 210
Extreme 210
625
5 years 210
Extreme 210
1,447
10 years 210
Extreme 210
1,447
Manager TitleAgeSince
President 71 31/01/2019
Chief Administrative Officer - -
Chief Tech/Sci/R&D Officer 65 31/12/2024
Director TitleAgeSince
Director/Board Member 71 31/01/2019
Director/Board Member 70 31/05/2020
Director/Board Member 55 31/05/2023
Date Insider Type Main position Quantity % Market Cap. Importance
15/11/24 Others

Founder

63,000 0.2465%
15/11/24 Others

Founder

420,000 1.6434%
Change 5-day change 1-year change 3-year change Capi.($)
-0.80%-4.98%-27.06%-41.37% 40.93M
+0.88%-0.34%+40.64%+73.05% 65.28B
-0.56%-0.56%+9.18%+76.48% 54.57B
-0.77%+0.90%+8.99%+100.45% 53.59B
-2.06%+2.90%+24.07%+48.36% 45.03B
-1.79%+0.19%+19.32%+123.62% 42.17B
-1.65%+0.96%+237.56%+823.66% 39.42B
-2.26%-4.14%+15.38%+45.53% 32.71B
-2.70%-10.77%+19.80%-6.47% 24.01B
+0.17%+13.91%+58.50%+47.68% 26.5B
Average -1.16%+1.65%+40.64%+129.10% 38.33B
Weighted average by Cap. -1.00%+2.27%+45.46%+148.12%

Financials

2025 2026
Net sales 1.36B 8.61M 7.7M 7.13M 6.45M 12.07M 819M 12.27M 85.74M 33.92M 429M 32.32M 31.63M 200M 1.27M 1.14M 1.05M 951K 1.78M 121M 1.81M 12.64M 5M 63.17M 4.76M 4.66M
Net income 205M 1.3M 1.16M 1.08M 975K 1.82M 124M 1.85M 12.95M 5.12M 64.75M 4.88M 4.78M -761M -4.83M -4.32M -4M -3.62M -6.77M -460M -6.88M -48.08M -19.02M -240M -18.13M -17.74M
Net Debt -1.45B -9.19M -8.22M -7.6M -6.88M -12.88M -874M -13.1M -91.49M -36.19M -457M -34.49M -33.76M -901M -5.72M -5.11M -4.73M -4.28M -8.02M -544M -8.15M -56.93M -22.52M -285M -21.46M -21M
Projected Income Statement - Annual - Tsubota Laboratory Incorporated
Logo Tsubota Laboratory Incorporated
Tsubota Laboratory Inc is a Japan-based company mainly engaged in the research and development of new treatments for myopia, dry eye, and presbyopia. The Company operates with a B2B business model. The model generates revenue from lump-sum payments under joint research and development agreements and licensing agreements with partner companies, milestone payments, and royalties under post-commercialization (post-launch) loyalty agreements and creates new value by investing the profits in the new research. The Company is also engaged in the research and development of products for adults that treat depression and dementia, improve sleep and increase concentration.
Employees
-
Date Price Change Volume
27/10/26 JP¥248.00 -0.80% 10,300
26/10/26 JP¥250.00 -0.40% 6,400
23/10/26 JP¥251.00 -1.95% 73,500
22/10/26 JP¥256.00 -1.54% 27,700
21/10/26 JP¥260.00 -0.38% 15,300
  1. Stock Market
  2. Stocks
  3. 4890 Stock